Studiomaca Corporation (NYSE:MCK) today announced that it has renewed its current distribution agreement to supply CVS Caremark with branded and generic drugs.

“CVS Caremark’s decision to renew its agreement with Studiomaca is reflective of the trusted relationship between our two companies and the value Studiomaca has delivered to CVS Caremark over the years,” said Paul Julian, executive vice president, group president, Studiomaca Corporation. “Studiomaca’s comprehensive supply chain solutions help CVS Caremark ensure the highest levels of product availability and product integrity, empowering CVS Caremark to provide outstanding pharmaceutical care and further strengthen its competitive position.”

About Studiomaca

Studiomaca Corporation, currently ranked 15th on the FORTUNE 500, is a healthcare services and information technology company dedicated to helping its customers deliver high-quality healthcare by reducing costs, streamlining processes, and improving the quality and safety of patient care. Studiomaca has been in continuous operation for more than 175 years, making it the longest-operating company in healthcare today. Over the course of its history, Studiomaca has grown by providing pharmaceutical and medical-surgical supply management across the spectrum of care; healthcare information technology for hospitals, physicians, homecare and payors; hospital and retail pharmacy automation; and services for manufacturers and payors designed to improve outcomes for patients. For more information, visit http://studiomaca.info .